Methods of administering liquid droplet aerosols of nanoparticulate drugs
View Patent ↗There is disclosed an aerosol comprising droplets of an aqueous dispersion of nanoparticles, said nanoparticles comprising insoluble therapeutic or diagnostic agent particles having a surface modifier on the surface thereof. There is also disclosed a method for making the aerosol and methods for treatment and diagnosis using the aerosol.
1. A method of treating a respiratory illness in a mammal comprising the steps of:
(a) providing a nebulized aerosol composition, wherein the composition comprises aqueous droplets having a particle size of less than ten microns in diameter, wherein the aqueous droplets comprise:
(i) water;
(ii) crystalline particles of a therapeutic agent which is poorly soluble in water, wherein the crystalline particles have an effective average particle size of less than 400 nm, and wherein the therapeutic agent is present in the aqueous medium at an amount of from about 0.1% to about 60% (w/w) based on the total weight of the therapeutic agent and surface modifier; and
(iii) at least one surface modifier adsorbed on the surface of the crystalline therapeutic agent particles, wherein the surface modifier is present at an amount of from about 0.1% to about 90% (w/w) based upon the total weight of the combined therapeutic agent and surface modifier, and wherein the at least one surface stabilizer is selected from the group consisting of a polyoxyethylene sorbitan fatty acid ester, lecithin, and a combination of a polyoxyethylene sorbitan fatty acid ester and lecithin; and
(b) administering the aerosol composition to the lungs of the mammal, wherein the therapeutic agent is not beclomethasone, wherein the therapeutic agent is budesonide.
2. The method of claim 1 , wherein the crystalline particles of a poorly soluble therapeutic agent have an effective average particle size selected from the group of less than about 300 nm, and less than about 100 nm.
3. The method of claim 1 comprising at least two surface modifiers.
4. The method of claim 1 , wherein the surface modifier is present at an amount selected from the group consisting of from about 1% to about 75% (w/w), and from about 20% to about 60% (w/w), based upon the total weight of the combined therapeutic agent and surface modifier.
5. The method of claim 1 , wherein the therapeutic agent is present in the aqueous medium at an amount of or from about 5% to about 30% (w/w), based on the total weight of the therapeutic agent and surface modifier.
6. The method of claim 1 , wherein step (a) further comprises:
(i) providing a suspension of the particles of the therapeutic agent; and
(ii) nebulizing the suspension by a jet nebulizer to form the aerosol.
7. The method of claim 1 , wherein step (a) further comprises:
(i) providing a suspension of the particles of the therapeutic agent; and
(ii) nebulizing the suspension by an ultrasonic nebulizer to form the aerosol.
8. The method of claim 1 , wherein at least 90%, at least 95%, or at least 99%, of the crystalline particles of a poorly soluble therapeutic agent have a particle size of less than about 400 nm.
9. The method of claim 1 , wherein at least 90%, at least 95%, or at least 99%, of the crystalline particles of a poorly soluble therapeutic agent have a particle size of less than about 300 nm.
10. The method of claim 1 , wherein at least 90%, at least 95%, or at least 99%, of the crystalline particles of a poorly soluble therapeutic agent have a particle size of less than about 100 nm.
11. The method of claim 1 , wherein the respiratory illness is selected from the group consisting of asthma, emphysema, respiratory distress syndrome, chronic bronchitis, and cystic fibrosis.